CLAIMS

1. Association of a selective and specific sinus node I_f current inhibitor and an agent that inhibits angiotensin-converting enzyme for use in the treatment of heart failure.

2. Association according to claim 1, characterised in that the heart failure treated is heart failure with preserved systolic function.

3. Association according to one of claims 1 or 2, characterised in that the selective and specific sinus node I_f current inhibitor is:
   - ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]-methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2*H*-3-benzazepin-2-one, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, or
   - *N*-{[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms.

4. Association according to one of claims 1 to 3, characterised in that the selective and specific sinus node I_f current inhibitor is ivabradine, in the form of the hydrochloride, or one of its hydrates or crystalline forms.

5. Association according to one of claims 1 to 3, characterised in that the selective and specific sinus node I_f current inhibitor is *N*-{[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine, in the form of the hydrochloride or fumarate, or one of their hydrates or crystalline forms.

6. Association according to one of claims 1 to 5, characterised in that the agent that inhibits angiotensin-converting enzyme is perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms.

7. Association according to claim 6, characterised in that the perindopril is in the form of a *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

8. Association according to one of claims 1 or 2, characterised in that the selective and specific sinus node I_f current inhibitor is ivabradine, in the form of the hydrochloride or one of its hydrates or crystalline forms, and the agent that inhibits angiotensin-converting enzyme is perindopril, in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

9. Association according to one of claims 1 or 2, characterised in that the selective and specific sinus node I_f current inhibitor is *N*-{[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine, in the form of the hydrochloride or fumarate or one of their hydrates or crystalline forms, and the agent that inhibits angiotensin-converting enzyme is perindopril, in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

10. Pharmaceutical compositions comprising as active ingredients:

- ivabradine, in the form of the hydrochloride or one of its hydrates or crystalline forms, and
- perindopril, in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms,

on their own or in combination with one or more pharmaceutically acceptable excipients,

for use in the treatment of heart failure.

11. Pharmaceutical compositions according to claim 10, characterised in that the heart failure treated is heart failure with preserved systolic function.

12. Pharmaceutical compositions comprising as active ingredients:

- *N*-{[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine, in the form of the hydrochloride or fumarate or one of their hydrates or crystalline forms, and
- perindopril, in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms,

on their own or in combination with one or more pharmaceutically acceptable excipients.

13. Pharmaceutical compositions according to claim 12, for use in the treatment of heart failure.

14. Pharmaceutical compositions according to claim 13, characterised in that the heart failure treated is heart failure with preserved systolic function.

15. Association of *N*-{[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine or one of its addition salts with a pharmaceutically acceptable acid, their hydrates or crystalline forms, and perindopril, in the form of the *tert*-butylamine or arginine salt, or one of their hydrates or crystalline forms.

16. Association according to claim 15, characterised in that *N*-{[(7*S*)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}-3-(7,8-dimethoxy-1,2,4,5-tetrahydro-3*H*-3-benzazepin-3-yl)-*N*-methyl-3-oxo-1-propanamine is in the form of the hydrochloride or fumarate or one of their hydrates or crystalline forms.

CLAIMS

1. Association of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl}-7,8-dimethoxy-1,3,4,5-tetrahydro-2*H*-3-benzazepin-2-one, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, with perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms, for use in the treatment of heart failure with preserved systolic function.

2. Association according to claim 1, characterised in that ivabradine is in the form of a hydrochloride, or one of its hydrates or crystalline forms.

3. Association according to one of claims 1 to 2, characterised in that the perindopril is in the form of a *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

4. Association according to claim 1, characterised in that ivabradine is in the form of a hydrochloride or one of its hydrates or crystalline forms, and perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

5. Pharmaceutical compositions comprising as active ingredients:

- ivabradine, or one of its addition salts with a pharmaceutically acceptable acid, their hydrates and crystalline forms, and
- perindopril, or one of its addition salts with a pharmaceutically acceptable base, their hydrates or crystalline forms,

on their own or in combination with one or more pharmaceutically acceptable excipients,

for use in the treatment of heart failure with preserved systolic function.

6. Pharmaceutical composition according to claim 5, characterised in that ivabradine is in the form of a hydrochloride, or one of its hydrates or crystalline forms.

7. Pharmaceutical composition according to claim 5, characterised in that perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.

8. Pharmaceutical composition according to claim 5, characterised in that ivabradine is in the form of a hydrochloride or one of its hydrates or crystalline forms, and perindopril is in the form of the *tert*-butylamine or arginine salt or one of their hydrates or crystalline forms.